quinazolines has been researched along with Palmoplantaris Pustulosis in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CH; Chang, CN; Chang, CY; Cheng, HM; Fang, WY; Kuo, YZ; Lin, JY; Pan, SC; Wu, LW | 1 |
| Chen, H; Deng, Y; Ding, L; Guo, J; Huang, X; Li, H; Tan, F; Wang, Y; Yang, G; Yu, B; Yu, P | 1 |
| Chen, M; Li, Y; Tang, F; Tong, M; Wen, H; Xiao, R; Zhang, G; Zhao, M | 1 |
| Liu, L; Lou, H; Ruan, Z; Shen, Y; Zheng, M; Zhou, J | 1 |
| Fu, LX; Tang, DM; Wang, Y; Yan, HX; Yang, XN | 1 |
| Boots, AMH; He, X; Joosten, I; Keijsers, R; Koenen, HJPM; Koerber, A; Smeets, RL; van de Kerkhof, PC; van Rijssen, E | 1 |
| Brown, CW; Campbell, TM | 1 |
| Futamura, K; Hashimoto, N; Matsumoto, K; Muro, Y; Nagasaka, T; Nishizawa, Y; Saito, H; Sugiura, K; Tomita, Y; Usukura, J | 1 |
| Manicassamy, S | 1 |
| Albert, R; Beerli, C; Cooke, NG; Cottens, S; Evenou, JP; Faller, B; Jean, C; Sedrani, R; von Matt, P; Wagner, J; Weckbecker, G; Wiegand, H; Zenke, G | 1 |
| Altman, A; Kong, KF | 1 |
| Griesinger, F; Overbeck, TR | 1 |
| Selam, M | 1 |
| Hussar, DA | 1 |
| Bamias, A; Efstathiou, E; Stratigos, A; Zorzou, MP | 1 |
| McCormack, JJ | 1 |
| Baudin, M; Christophers, E; Dupuy, P; Goos, M; van de Kerkhof, PC | 1 |
| Ben-Bassat, H; Chaouat, M; Chen, H; Gazit, A; Harzstark, Z; Klein, BY; Levitzki, A; Levitzki, R; McCollough, J; McMahon, J; Narog, B; Powell, TJ; Shawver, L; Shenoy, N; Tang, C | 1 |
| Skrifvars, B | 1 |
| Hynes, JB; McCullough, JL; Weinstein, GD | 1 |
3 review(s) available for quinazolines and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Topics: Animals; Clinical Trials as Topic; Graft Rejection; Humans; Organ Transplantation; Protein Kinase C; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines | 2009 |
Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Treatment Outcome | 2012 |
Dihydrofolate reductase inhibitors as potential drugs.
Topics: Aminopterin; Animals; Antimalarials; Bacterial Infections; Biological Transport; Drug Interactions; Folic Acid; Folic Acid Antagonists; Helminthiasis; Humans; Immunosuppressive Agents; Leukemia, Experimental; Liver; Methotrexate; Mice; Mycoses; Neoplasms; Protozoan Infections; Psoriasis; Quinazolines; Rats; Receptors, Drug; Trypanosoma cruzi | 1981 |
2 trial(s) available for quinazolines and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study.
Topics: Adult; Crown Ethers; Double-Blind Method; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Quinazolines | 2019 |
Inhibitor of the release of mast cell mediators does not improve the psoriatic plaque.
Topics: Adult; Cell Degranulation; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Mast Cells; Middle Aged; Psoriasis; Quinazolines | 1995 |
15 other study(ies) available for quinazolines and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
The anti-TH17 polarization effect of Indigo naturalis and tryptanthrin by differentially inhibiting cytokine expression.
Topics: Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Endothelial Cells; Humans; I-kappa B Kinase; Immunosuppressive Agents; Inflammation Mediators; Jurkat Cells; Keratinocytes; Mice, Knockout; Nuclear Receptor Subfamily 1, Group F, Member 3; Phenotype; Psoriasis; Quinazolines; Skin; Th17 Cells; U937 Cells | 2020 |
Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models.
Topics: Animals; Cell Line, Tumor; Crown Ethers; Epithelial Cells; ErbB Receptors; Female; Guinea Pigs; Humans; Mice; Mice, Inbred ICR; Mitosis; Models, Animal; Neovascularization, Pathologic; Psoriasis; Quinazolines; Signal Transduction | 2018 |
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Indole Alkaloids; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Quinazolines; Signal Transduction; Skin; Skin Diseases; Th17 Cells; Toll-Like Receptor 7 | 2019 |
A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis.
Topics: Animals; Capillary Permeability; Disease Models, Animal; Inflammation; Mice; Mice, Transgenic; Neovascularization, Pathologic; Psoriasis; Quinazolines; Skin; T-Lymphocytes; Thiadiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.
Topics: Biopsy; CD28 Antigens; Cell Proliferation; Coculture Techniques; Cytokines; Forkhead Transcription Factors; Homeostasis; Humans; Interferon-gamma; Interleukin-17; Interleukin-1beta; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Protein Kinase C; Psoriasis; Pyrroles; Quinazolines; Skin; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory | 2014 |
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Topics: Acneiform Eruptions; Aged; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Male; Protein Kinase Inhibitors; Psoriasis; Quinazolines | 2008 |
The unfolded protein response is activated in differentiating epidermal keratinocytes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Immunohistochemistry; Keratinocytes; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Middle Aged; Protein Disulfide-Isomerases; Protein Folding; Protein Transport; Psoriasis; Quinazolines; Regulatory Factor X Transcription Factors; RNA, Messenger; Signal Transduction; Transcription Factors; Ubiquitin-Protein Ligases; X-Box Binding Protein 1 | 2009 |
Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.
Topics: Animals; Cells, Cultured; Graft Rejection; Humans; Lymphocyte Activation; Macaca fascicularis; Mice; Mice, Inbred BALB C; Protein Kinase C; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Rats; Structure-Activity Relationship; Tissue Distribution | 2011 |
PKCθ: a new target for selective immunosuppression.
Topics: Animals; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppression Therapy; Isoenzymes; Mice; Mice, Knockout; Molecular Targeted Therapy; NF-kappa B; Protein Kinase C; Protein Kinase C-theta; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Signal Transduction; T-Lymphocytes | 2012 |
Psoriasis aggravation due to lapatinib.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Psoriasis; Quinazolines | 2013 |
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Recurrence; Severity of Illness Index | 2004 |
Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.
Topics: Animals; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermis; ErbB Receptors; Humans; Keratinocytes; Mice; Psoriasis; Quinazolines; Skin Absorption; Tumor Cells, Cultured; Tyrphostins | 1999 |
Influence of proquazone (Biarison) on the levels of complement components (C3 and C4) in synovial fluid and on IgM in serum in patients with active rheumatoid arthritis. A preliminary report.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Complement C3; Complement C4; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Joint Diseases; Male; Middle Aged; Psoriasis; Quinazolines; Synovial Fluid | 1978 |
In vitro screening of biochemical activity of folic acid antagonists in skin.
Topics: Animals; Animals, Newborn; Chlorobenzenes; Depression, Chemical; DNA; Folic Acid Antagonists; Methotrexate; Psoriasis; Pyrimethamine; Pyrimidines; Quinazolines; Rats; Skin; Tetrahydrofolate Dehydrogenase; Triazines; Trimethoprim | 1977 |